Table of Contents Author Guidelines Submit a Manuscript
Tuberculosis Research and Treatment
Volume 2010 (2010), Article ID 938178, 6 pages
http://dx.doi.org/10.1155/2010/938178
Research Article

Low Occurrence of Tuberculosis Drug Resistance among Pulmonary Tuberculosis Patients from an Urban Setting, with a Long-Running DOTS Program in Zambia

1Biomedical Sciences Department, Tropical Diseases Research Centre, P.O. Box 71769, Ndola, Zambia
2Mycobacteriology Unit, Institute of Tropical Medicine, Naionalestraat 155, B-2000 Antwerpen, Belgium
3National Tuberculosis and Leprosy Program, Ministry of Health, P.O. Box 30205, Lusaka, Zambia
4Ndola District Health Management Team, P.O. Box 70672, Ndola, Zambia
5Tuberculosis Research Section, National Institutes of Health, LCID/NIAID, Bethesda, MD 20892, USA
6Department of Biomedical Sciences, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, 2000 Antwerpen, Belgium

Received 2 December 2009; Revised 27 April 2010; Accepted 18 May 2010

Academic Editor: Nalin Rastogi

Copyright © 2010 Chanda Mulenga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. The World Health Organization, “Global tuberculosis control WHO report,” WHO/HTM/TB/2009.411, WHO, Geneva, Switzerland, 2009. View at Google Scholar
  2. Central Statistical Office (CSO), Ministry of Health (MOH), Tropical Diseases Research Centre (TDRC), University of Zambia (UNZA), and Macro International Inc., Zambia Demographic and Health Survey 2007, CSO and Macro International Inc, Calverton, Md, USA, 2009.
  3. J. B. Harris, S. M. Hatwiinda, K. M. Randels et al., “Early lessons from the integration of tuberculosis and HIV services in primary care centers in Lusaka, Zambia,” International Journal of Tuberculosis and Lung Disease, vol. 12, no. 7, pp. 773–779, 2008. View at Google Scholar · View at Scopus
  4. The World Health Organization, “WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis Drug Resistance in the World, Report No. 4,” WHO/HTM/TB/2008.394, WHO, Geneva, Switzerland, 2008. View at Google Scholar
  5. C. Habeenzu, S. Mitarai, D. Lubasi et al., “Tuberculosis and multidrug resistance in Zambian prisons, 2000-2001,” International Journal of Tuberculosis and Lung Disease, vol. 11, no. 11, pp. 1216–1220, 2007. View at Google Scholar · View at Scopus
  6. Central Statistics Office, “Zambia 2000 Census of Population and Housing,” Summary Report, Lusaka, Zambia, 2003. View at Google Scholar
  7. Ministry of Health, Tuberculosis and TB/HIV Manual, The National TB and Leprosy Control Programme, Lusaka, Zambia, 3rd edition.
  8. The World Health Organization, Treatment of Tuberculosis: Guidelines for National Programmes, WHO/CDS/TB/2003.313, WHO, Geneva, Switzerland, 3rd edition, 2003.
  9. The World Health Organization, Guidelines for Surveillance of Drug Resistance in Tuberculosis, WHO/HTM/TB/2009.422, WHO, Geneva, Switzerland, 4th edition, 2008.
  10. S. A. Petroff., “A new and rapid method for the isolation and cultivation of tubercle bacilli directly form the sputum and feces,” The Journal of Experimental Medicine, vol. 21, no. 1, pp. 38–42, 1915. View at Google Scholar
  11. P. T. Kent and G. P. Kubica, Public Health Mycobacteriology—A Guide for a Level III Laboratory, Centers for Disease Control, Atlanta, Ga, USA, 1985.
  12. G. Canetti, W. Fox, A. Khomenko et al., “Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes,” Bulletin of the World Health Organization, vol. 41, no. 1, pp. 21–43, 1969. View at Google Scholar · View at Scopus
  13. L. Rigouts, O. Nolasco, P. de Rijk et al., “Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis,” Journal of Clinical Microbiology, vol. 45, no. 1, pp. 252–254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Telenti, N. Honoré, C. Bernasconi et al., “Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level,” Journal of Clinical Microbiology, vol. 35, no. 3, pp. 719–723, 1997. View at Google Scholar · View at Scopus
  15. A. P. Davies, O. J. Billington, B. A. Bannister, W. R. C. Weir, T. D. McHugh, and S. H. Gillespie, “Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed mulit-drug resistance during the course of treatment,” Journal of Infection, vol. 41, no. 2, pp. 184–187, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. The World Health Organization, “TB Country Profile, Zambia,” http://www.who.int/countries/zmb/en/.
  17. S. Ramaswamy and J. M. Musser, “Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis,” Tubercle and Lung Disease, vol. 79, no. 1, pp. 3–29, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. O. O. Simooya, N. E. Sanjobo, L. Kaetano et al., “'Behind walls: a study of HIV risk behaviours and seroprevalence in prisons in Zambia,” AIDS, vol. 15, no. 13, pp. 1741–1744, 2001. View at Google Scholar · View at Scopus
  19. M. Sanders, A. Van Deun, D. Ntakirutimana et al., “Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey,” International Journal of Tuberculosis and Lung Disease, vol. 10, no. 2, pp. 178–183, 2006. View at Google Scholar · View at Scopus
  20. D. Affolabi, O. A. Adjagba, B. Tanimomo-Kledjo, M. Gninafon, S. Y. Anagonou, and F. Portaels, “Anti-tuberculosis drug resistance among new and previously treated pulmonary tuberculosis patients in Cotonou, Benin,” International Journal of Tuberculosis and Lung Disease, vol. 11, no. 11, pp. 1221–1224, 2007. View at Google Scholar · View at Scopus
  21. S. Homolka, E. Post, B. Oberhauser et al., “High genetic diversity among Mycobacterium tuberculosis complex strains from Sierra Leone,” BMC Microbiology, vol. 8, article no. 103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. S. Jarallah, A. K. Elias, M. S. Al Hajjaj, M. S. Bukhari, A. H. M. Al Shareef, and S. A. Al-Shammari, “High rate of rifampicin resistance of Mycobacterium tuberculosis in the Taif region of Saudi Arabia,” Tubercle and Lung Disease, vol. 73, no. 2, pp. 113–115, 1992. View at Publisher · View at Google Scholar · View at Scopus
  23. S. S. Munsiff, S. Joseph, A. Ebrahimzadeh, and T. R. Frieden, “Rifampin-monoresistant tuberculosis in New York City, 1993-1994,” Clinical Infectious Diseases, vol. 25, no. 6, pp. 1465–1467, 1997. View at Google Scholar · View at Scopus
  24. R. Ridzon, C. G. Whitney, M. T. McKenna et al., “Risk factors for rifampin mono-resistant tuberculosis,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 6, part 1, pp. 1881–1884, 1998. View at Google Scholar · View at Scopus
  25. M. Lutfey, P. Della-Latta, V. Kapur et al., “Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS,” American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 2, pp. 837–840, 1996. View at Google Scholar · View at Scopus
  26. F. March, X. Garriga, P. Rodríguez et al., “Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis,” Clinical Infectious Diseases, vol. 25, no. 5, pp. 1044–1047, 1997. View at Google Scholar · View at Scopus
  27. C. M. Nolan, D. L. Williams, M. D. Cave et al., “Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis,” American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 3, pp. 1067–1071, 1995. View at Google Scholar · View at Scopus
  28. G. Ramachandran, A. K. H. Kumar, C. Padmapriyadarsini et al., “Urine levels of rifampicin & isoniazid in asymptomatic HIV-positive individuals,” Indian Journal of Medical Research, vol. 125, no. 6, pp. 763–766, 2007. View at Google Scholar · View at Scopus
  29. L. Sandman, N. W. Schluger, A. L. Davidow, and S. Bonk, “Risk factors for rifampin-monoresistant tuberculosis: a case-control study,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 2, pp. 468–472, 1999. View at Google Scholar · View at Scopus
  30. Ministry of Health, Zambia 2006, Antenatal Clinic Sentinel Surveillance Survey, Lusaka, Zambia, 2009.
  31. P. Bifani, B. Mathema, N. Kurepina et al., “The evolution of drug resistance in Mycobacterium tuberculosis: from a mono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population,” Journal of Infectious Diseases, vol. 198, no. 1, pp. 90–94, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Umubyeyi, L. Rigouts, I. C. Shamputa, A. Dediste, M. Struelens, and F. Portaels, “Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda,” International Journal of Infectious Diseases, vol. 12, no. 2, pp. 152–156, 2008. View at Publisher · View at Google Scholar · View at Scopus